Sector News

Bayer, Sensyne to form new AI ‘LifeHub’

October 10, 2019
Life sciences

Sensyne has announced a new partnership – its second this week – with Bayer, in order to accelerate the development of new treatments using clinical artificial intelligence.

The company revealed that it will work in partnership with the German pharma giant on novel projects at the LifeHub UK, including its inaugural project – the development of AI-enabled radiology to enhance patient outcomes.

LifeHub UK, which launches today, forms part of a global network of Bayer innovation hubs, designed to accelerate and optimise disease detection and data-driven drug discovery by enabling Artificial Intelligence (AI)-enabled imaging solutions.

The companies have announced that the first LifeHub UK project will focus on the development of AI-enabled radiology solutions using Sensyne Health’s proprietary clinical AI technology platform to identify digital solutions for automated image evaluation.

The project will analyse research from three million anonymised, ethically sourced NHS patient records and imaging data provided through Sensyne Health’s partnerships with NHS trusts, developing digital solutions to help radiologists improve the quality of the diagnosis and increase efficiency for patients receiving the right treatment in a timely manner.

Kemal Malik, Bayer board member for innovation, said that the company is “delighted to launch LifeHub UK,” and that it firmly believes “artificial intelligence has transformative potential for healthcare, leading to enhancements in prediction, prevention and personalised treatments.

“LifeHub UK’s roadmap is a perfect fit to Bayer’s Open Innovation strategy, which is designed to leverage places, programmes and partnerships – such as strategic alliances and joint ventures – in the life sciences fields of pharmaceuticals and agriculture.”

Earlier this week Sensyne announced a formal research agreement with the UK Medicines and Healthcare Products Regulatory Agency (MHRA), to contribute to the development of methods to validate software algorithms used in digital health.

The company is also already part of a partnership with the University of Oxford’s Big Data Institute (BDI), using data science and clinical artificial intelligence (clinical AI) for the patient-centred management and treatment of chronic disease.

By Anna Smith

Source: Pharma Times

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”